Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 11/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 3/20 | 0.47 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5283007 | 0.90 | SCD (0.45) | SCDFPR2PROKR1MEN1KMT2A | |
| SCHEMBL5244612 | 0.87 | NPC1 (0.53) | SCDTP53MAPTFPR2PROKR1 | |
| SCHEMBL1471602 | 0.81 | KMT2A (0.65) | SCDMEN1KMT2A | |
| SCHEMBL5243713 | 0.79 | ALDH1A1 (0.43) | TP53MAPTMEN1KMT2A | |
| SCHEMBL5290061 | 0.79 | SCD (0.47) | SCDFPR2PROKR1 | |
| SCHEMBL5284546 | 0.77 | KMT2A (0.56) | MAPTMEN1KMT2A | |
| SCHEMBL1471706 | 0.74 | HSD11B1 (0.54) | SCDTP53FPR2PROKR1MEN1 | |
| SCHEMBL3222938 | 0.73 | MEN1 (0.63) | SCDTP53MAPTFPR2PROKR1 | |
| SCHEMBL3223105 | 0.71 | KMT2A (0.60) | MEN1KMT2A | |
| SCHEMBL1471495 | 0.71 | TP53 (0.62) | SCDTP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758873-A1 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282818-A1 | Ubiquitin ligase inhibitors | NEDD4, TRAF6, XIAP | SCD 3511/4885TP53 293/4885MAPT 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.